Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA VOYAGE Study in Children with Asthma

 Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA VOYAGE Study in Children with Asthma

Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA VOYAGE Study in Children with Asthma

Shots:

  • The P-III LIBERTY ASTHMA VOYAGE study involves assessing of Dupixent (SC, 100/200mg, q2w ) + SOC maintenance therapy of medium-dose ICS with a second controller medication/ high-dose ICS with/out second controller medication vs PBO in 408 children 6 to <12 years old with uncontrolled moderate-severe asthma
  • Results: Patients with baseline blood EOS ≥300 cells/μl and patients with markers of type 2 inflammation (FeNO ≥20 ppb or EOS ≥150 cells/μl), reduction in the rate of asthma attacks, with 65% & 59% average reduction over 1yr. (0.24 and 0.31 vs 0.67 and 0.75 events/year), improvement in lung function @12wks. (10.15 and 10.53 vs 4.83 and 5.32); improvement in lung function was observed as early as 2wks.and was sustained for up to 52wks. respectively
  • Dupixent is a mAb that inhibits the signaling of the IL-4 & IL-13 proteins with its expected regulatory submissions in the US & EU for children aged 6-11 yrs. in Q1’21

    Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: BioPharma Reporter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post